Healthcare Resource Utilization and Costs Associated with Acute COVID in Adult Patients Managed in the Community or Hospital Setting in England: A Population-Based Study
Author(s)
Yang J1, Andersen K2, Rai K3, Reimbaeva M4, McGrath LJ4, Tsang C5, Tritton T3, Payne P3, Backhouse B3, Mugwagwa T6, Naicker K5, Mendes D5, Alfred T4, Araghi M5, Wood RP3, Nguyen JL1
1Pfizer Inc., New York, NY, USA, 2Pfizer Inc, Washington, DC, USA, 3Adelphi Real World, Bollington, UK, 4Pfizer Inc, New York, NY, USA, 5Pfizer UK, Tadworth, UK, 6Pfizer UK, Thame, OXF, UK
Presentation Documents
OBJECTIVES:
The COVID pandemic has imposed significant direct medical cost and resource use burden on healthcare systems. This study described the patient demographic and clinical characteristics, healthcare resource utilization and costs associated with acute COVID in adults in England.
METHODS:
This population-based retrospective study used linked primary care (Clinical Practice Research Datalink, CPRD, Aurum) and secondary care (Hospital Episode Statistics) data to identify: 1) hospitalized (admitted within 12 weeks of a positive COVID-19 PCR test between August 2020 and March 2021) and 2) non-hospitalized patients (positive test between August 2020 and January 2022 and managed in the community). Hospitalization and primary care costs, 12 weeks after COVID diagnosis, were calculated using 2021 UK healthcare reference costs.
RESULTS:
We identified 1,706,368 adult COVID cases. For hospitalized (n=13,105) and non-hospitalized (n=1,693,263) cohorts, 84% and 41% considered high risk for severe COVID using PANORAMIC criteria and 41% and 13% using the UKHSA’s Green Book for prioritized immunization groups, respectively. Among hospitalized cases, median (IQR) length of stay was 5 (2-7), 6 (4-10), 8 (5-14) days for 18-49 years, 50-64 years and ≥ 65 years, respectively; 6% required mechanical ventilation support, and median (IQR) healthcare costs (critical care cost excluded) per-finished consultant episode due to COVID increased with age (18-49 years: £4364 (£1362-£4471), 50-64 years: £4379 (£4364-£5800), 65-74 years: £4395 (£4364-£5800), 75-84 years: £4473 (£4364-£5800) and 85+ years: £5800 (£4370-£5807). Among non-hospitalized cases, older adults were more likely to seek GP consultations (13% of persons age 85+, 9% age 75-84, 7% age 65-74, 5% age 50-64, 3% age 18-49). Of those with at least 1 GP visit, the median primary care consultation total cost in the non-hospitalized cohort was £16 (IQR 16-31).
CONCLUSIONS:
Our results quantify the substantial economic burden required to manage adult patients in the acute phase of COVID in England.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EE236
Topic
Economic Evaluation, Study Approaches
Topic Subcategory
Electronic Medical & Health Records
Disease
Vaccines